UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
Portfolio Pulse from Vandana Singh
AstraZeneca's CEO Pascal Soriot has urged the UK government to review its drug pricing assessment after NICE deemed the company's breast cancer drug Enhertu too expensive. Enhertu, developed with Daiichi Sankyo, has shown significant results but may not be available for treating advanced breast cancer in England due to its high cost. Despite challenges, AstraZeneca reported robust sales growth, with Enhertu contributing significantly.
July 26, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca's breast cancer drug Enhertu has been deemed too expensive by NICE, potentially limiting its availability in England. CEO Pascal Soriot has called for a review of drug pricing assessments. Despite this, AstraZeneca reported strong sales growth, with Enhertu contributing significantly.
The news highlights a regulatory challenge for AstraZeneca's Enhertu in the UK, which could limit its market. However, the company's overall strong sales growth and significant contribution from Enhertu balance the short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100